7/17/26 -5%

Market volatility dictates trading strategy, with a focus on the memory sector and biotech pipelines. Micron remains a central interest, as current DRAM and HBM demand suggests a bullish trajectory despite temporary market panics and leverage-driven liquidations. Biotech investment requires extreme caution, particularly regarding phase-three trials where high failure rates and questionable data often undermine long-term value. Companies like Exelixis and Abbott Labs undergo scrutiny for their growth potential and product pipelines, highlighting the necessity of deep industry knowledge to navigate complex clinical and commercial landscapes. Successful trading relies on identifying shifts in market perception rather than fundamental analysis alone, while scaling capital remains the primary challenge for sustained profitability. AI-driven tools are increasingly essential for processing data, yet the core of investment success remains the ability to distinguish between genuine innovation and industry hype.